Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06598306 · ClinicalTrials.gov registry record · Phase 1

Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

A Phase 1 study of Extensive-stage Small-cell Lung Cancer, sponsored by Amgen.

Recruiting
Registry status
Phase 1
Development phase
220
Enrollment target
20
Study locations

NCT06598306 is a Phase 1 study of Extensive-stage Small-cell Lung Cancer that is actively recruiting participants, run by Amgen. The registered enrollment target is 220 participants, above the 167-participant average among 25 other Extensive-stage Small-cell Lung Cancer trials with a reported enrollment target (32% higher). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06598306, a Phase 1 study of Extensive-stage Small-cell Lung Cancer, is actively recruiting participants, sponsored by Amgen.

RECRUITING
Registry status
Phase 1
Development phase
220 participants
Enrollment target
20
Study locations

Study Summary

The primary objective of this study is to evaluate the safety and tolerability of subcutaneous (SC) tarlatamab.

Conditions Studied

Extensive-stage Small-cell Lung Cancer

Interventions

  • DRUG Tarlatamab

Study Locations (20)

Other

  • Universitair Ziekenhuis Gent - Ghent
  • Universitair Ziekenhuis Leuven - Campus Gasthuisberg - Leuven
  • Centre Hospitalier Universitaire de Liege - Sart Tilman - Liège
  • Universitaetsklinikum Regensburg - Regensburg
  • Universitaetsklinikum Wuerzburg - Würzburg
  • Wakayama Medical University Hospital - Wakayama
  • Uniwersyteckie Centrum Kliniczne - Gdansk
  • Instytut Centrum Zdrowia Matki Polki - Lodz
  • Wojewodzki Szpital im Sw Ojca Pio w Przemyslu - Przemyśl

New South Wales

  • Chris OBrien Lifehouse - Camperdown
  • Calvary Mater Newcastle Hospital - Waratah

California

  • University of Southern California, Norris Comprehensive Cancer Center - Los Angeles

Illinois

  • University of Illinois Chicago - Chicago

Michigan

  • Trinity Health Saint Joseph Mercy Ann Arbor - Ann Arbor

South Dakota

  • Avera Cancer Institute - Sioux Falls

Texas

  • University of Texas MD Anderson Cancer Center - Houston

Washington

  • Swedish Cancer Institute - Seattle

Trial Details

FieldValue
Enrollment Target 220 participants
Start Date 2024-10-07
Est. Completion 2030-03-27
Phase Phase 1

Sponsor

Amgen

558 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06598306

The ClinicalTrials.gov registry entry for NCT06598306 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 167-participant average among 25 other Extensive-stage Small-cell Lung Cancer trials with a reported enrollment target (32% higher). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Extensive-stage Small-cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Tarlatamab is the first listed.

NCT06598306 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, New South Wales, California.

Frequently Asked Questions

What is clinical trial NCT06598306 about?

NCT06598306 is a clinical study titled "Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)". The primary objective of this study is to evaluate the safety and tolerability of subcutaneous (SC) tarlatamab.

What is the current status of trial NCT06598306?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 220 participants. The study started on 2024-10-07. Estimated completion is 2030-03-27.

What conditions does trial NCT06598306 study?

This clinical trial studies the following conditions: Extensive-stage Small-cell Lung Cancer.

What interventions are being tested in trial NCT06598306?

The interventions under investigation include: Tarlatamab (DRUG).

Who is sponsoring clinical trial NCT06598306?

This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06598306 being conducted?

This trial has 20 study locations across California, Illinois, Michigan, South Dakota, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Extensive-stage Small-cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Extensive-stage Small-cell Lung Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.